Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Nov 20

PMID 31739537

Citations 29

Authors

Erik Kudela

Marek Samec

Peter Kubatka

Marcela nachajova

Zuzana Laucekova

Alena Liskova

Karol Dokus

Kamil Biringer

Denisa Simova

Eva Gabonova

Zuzana Dankova

Kristina Biskupska Bodova

Pavol Zubor

Daniela Trog

Affiliations

Soon will be listed here.

Abstract

Why does healthcare of breast cancer (BC) patients, especially in a young population, matter and why are innovative strategies by predictive, preventive, and personalized medicine (PPPM) strongly recommended to replace current reactive medical approach in BC management? Permanent increase in annual numbers of new BC cases with particularly quick growth of premenopausal BC patients, an absence of clearly described risk factors for those patients, as well as established screening tools and programs represent important reasons to focus on BC in young women. Moreover, "young" BC cases are frequently "asymptomatic", difficult to diagnose, and to treat effectively on time. The objective of this article is to update the knowledge on BC in young females, its unique molecular signature, newest concepts in diagnostics and therapy, and to highlight the concepts of predictive, preventive, and personalized medicine with a well-acknowledged potential to advance the overall disease management.

Citing Articles

The functional TNF-αG > a single-nucleotide polymorphism (rs1800629): association with the predictive indices of breast cancer carcinogenesis.

Refaat S, Al-Rashidi H, El Azeem R, Nouh W, Hamed S, Attia Z Breast Cancer Res Treat. 2024; 210(1):57-70.

PMID: 39570546 PMC: 11787156. DOI: 10.1007/s10549-024-07536-y.

Development of a breast cancer risk assessment and primary prevention pathway for women aged 30-39 years: Views of UK primary care providers on the role of primary care.

Hindmarch S, Gorman L, Usher-Smith J, Woof V, Howell S, French D PLoS One. 2024; 19(9):e0308638.

PMID: 39269936 PMC: 11398678. DOI: 10.1371/journal.pone.0308638.

Outcomes of physical exercises on initiation, progression, and treatment of breast cancer.

Xu J, Jiao X, Bayat R Cell Commun Signal. 2024; 22(1):260.

PMID: 38715015 PMC: 11075339. DOI: 10.1186/s12964-024-01634-6.

The Efficacy of Paxman Scalp Cooling System in Preventing Hair Loss in Breast Cancer Patients Receiving Chemotherapy in Western India - Multi-centre Retrospective Cohort Study.

Mekha M, Joshi A, Maniar V, Maheshwari U, Joshi K, Kalaskar P Indian J Dermatol. 2024; 69(1):16-23.

PMID: 38572038 PMC: 10986862. DOI: 10.4103/ijd.ijd_345_23.

Multiplex electrochemical sensing platforms for the detection of breast cancer biomarkers.

OBrien C, Khor C, Ardalan S, Ignaszak A Front Med Technol. 2024; 6:1360510.

PMID: 38425422 PMC: 10902167. DOI: 10.3389/fmedt.2024.1360510.

References

Tang L, Jin X, Yang H, He M, Chang H, Shao Z . Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer. 2015; 15:201. PMC: 4389816. DOI: 10.1186/s12885-015-1207-z. View

Netea M, Kullberg B, van der Meer J . Circulating cytokines as mediators of fever. Clin Infect Dis. 2000; 31 Suppl 5:S178-84. DOI: 10.1086/317513. View

Lang K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S . Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol. 2015; 26(1):184-90. PMC: 4666282. DOI: 10.1007/s00330-015-3803-3. View

Covelli A, Baxter N, Fitch M, McCready D, Wright F . 'Taking control of cancer': understanding women's choice for mastectomy. Ann Surg Oncol. 2014; 22(2):383-91. DOI: 10.1245/s10434-014-4033-7. View

Pisano E, Hendrick R, Yaffe M, Baum J, Acharyya S, Cormack J . Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 2008; 246(2):376-83. PMC: 2659550. DOI: 10.1148/radiol.2461070200. View

Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L . The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012; 48(18):3355-77. DOI: 10.1016/j.ejca.2012.10.004. View

Hamam R, Hamam D, Alsaleh K, Kassem M, Zaher W, Alfayez M . Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017; 8(9):e3045. PMC: 5636984. DOI: 10.1038/cddis.2017.440. View

Evans D, Moran A, Hartley R, Dawson J, Bulman B, Knox F . Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer. 2010; 102(7):1091-8. PMC: 2853095. DOI: 10.1038/sj.bjc.6605606. View

Mencalha A, Victorino V, Cecchini R, Panis C . Mapping oxidative changes in breast cancer: understanding the basic to reach the clinics. Anticancer Res. 2014; 34(3):1127-40. View

10.

Rummel S, Lovejoy L, Shriver C, Ellsworth R . Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer. Breast Cancer Res Treat. 2017; 164(3):593-601. DOI: 10.1007/s10549-017-4291-8. View

11.

Bardia A, Hurvitz S . Targeted Therapy for Premenopausal Women with HR, HER2 Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. Clin Cancer Res. 2018; 24(21):5206-5218. DOI: 10.1158/1078-0432.CCR-18-0162. View

12.

Adank M, Hes F, van Zelst-Stams W, van den Tol M, Seynaeve C, Oosterwijk J . [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer]. Ned Tijdschr Geneeskd. 2015; 159:A8910. View

13.

Wang W, Wang X, Liu J, Gao J, Wang J, Wang X . Breast cancer in young women of Chinese Han population: A retrospective study of patients under 25 years. Pathol Res Pract. 2016; 212(11):1015-1020. DOI: 10.1016/j.prp.2016.08.010. View

14.

Nichols H, Berrington de Gonzalez A, Lacey Jr J, Rosenberg P, Anderson W . Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011; 29(12):1564-9. PMC: 3082975. DOI: 10.1200/JCO.2010.32.7395. View

15.

Golubnitschaja O, Filep N, Yeghiazaryan K, Blom H, Hofmann-Apitius M, Kuhn W . Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine. Amino Acids. 2017; 50(3-4):383-395. DOI: 10.1007/s00726-017-2524-0. View

16.

Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

17.

Zhao M, Tang Y, Kim H, Hasegawa K . Machine Learning With K-Means Dimensional Reduction for Predicting Survival Outcomes in Patients With Breast Cancer. Cancer Inform. 2018; 17:1176935118810215. PMC: 6238199. DOI: 10.1177/1176935118810215. View

18.

Polivka Jr J, Altun I, Golubnitschaja O . Pregnancy-associated breast cancer: the risky status quo and new concepts of predictive medicine. EPMA J. 2018; 9(1):1-13. PMC: 5833893. DOI: 10.1007/s13167-018-0129-7. View

19.

Azim Jr H, Partridge A . Biology of breast cancer in young women. Breast Cancer Res. 2014; 16(4):427. PMC: 4303229. DOI: 10.1186/s13058-014-0427-5. View

20.

Zhang X, Ju S, Wang X, Cong H . Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Clin Exp Med. 2019; 19(3):271-279. DOI: 10.1007/s10238-019-00563-w. View